Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match ...

Under the terms of the new agreement, Lonza will manufacture the mAb at Lonza’s biologics facility in Porriño (ES), occupying a majority of the site’s manufacturing capacity. The ADC will then be ...